116
Half of Weight Loss Drug Users Stop Treatment Within a Year, Study Finds
Vienna, Austria – The burgeoning popularity of new anti-obesity drugs like semaglutide (Ozempic, Wegovy) is facing a meaningful hurdle: adherence. A large, population-based study presented this week at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna reveals that roughly half of adults without diabetes in denmark discontinue semaglutide treatment within the first year of use.
The findings,
